Matches in SemOpenAlex for { <https://semopenalex.org/work/W3173728910> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W3173728910 endingPage "118" @default.
- W3173728910 startingPage "114" @default.
- W3173728910 abstract "Introduction: Heart failure (HF) places a significant economic burden on the health care system all over the world mainly due to frequent and repetitive hospitalizations. Thus, there is a need for both cost-effective and efficient therapeutic options. The aim of the study was to describe the economic aspect of levosimendan treatment in hospitalized HF patients in one major Polish cardiology unit. Material and methods: Retrospective observational study included 1086 patients with exacerbation of chronic HF, admitted to the Cardiology Department, University Hospital No 1 in Bydgoszcz, Poland in 2018–2020. We analyzed the cost of therapy, cost and the length of stay of 1057 hospitalizations of patients receiving standard therapy (ST) only and 29 hospitalizations of patients receiving levosimendan (Levo) on top. Levosimendan was used in patients not responding to standard therapy, mostly as a drug of the last chance. Results: The mean length of hospital stay for the ST patients was 9.4 days compared to 29.1 days for the Levo group. The median total cost of hospitalization of patients receiving ST was significantly lower compared to Levo group [PLN 6,612.5 (IQR 3,624.9—13,301.3) vs PLN 23,854.9 (IQR 10,900.4–40,391.5), p < 0.001]. On the other hand, the median daily cost of hospitalization did not differ between the ST and Levo group [PLN 772 (616.4–1,629) vs PLN 1,010.5 (IQR 787.4–1,172), p = 0.1]. The total cost of treatment was significantly lower only in the ST subgroup hospitalized for less than 2 weeks compared to the Levo group (p = 0.008). An early decision of levosimendan introduction (up to 8 days) resulted in a shorter hospitalization time compared to later drug administration (21 days vs 42 days; p = 0.019). Conclusions: Early administered levosimendan in HF exacerbation seems to be cost-effective in Polish clinical and economic settings. Despite the high cost of drug acquisition, it may provide better outcomes at lower overall costs of HF patient management. A randomized trial will be necessary to address this issue in Poland." @default.
- W3173728910 created "2021-07-05" @default.
- W3173728910 creator A5005207274 @default.
- W3173728910 creator A5019858389 @default.
- W3173728910 creator A5029840046 @default.
- W3173728910 creator A5030036503 @default.
- W3173728910 creator A5050751424 @default.
- W3173728910 creator A5067935886 @default.
- W3173728910 creator A5090902698 @default.
- W3173728910 date "2021-06-30" @default.
- W3173728910 modified "2023-09-27" @default.
- W3173728910 title "Cost-effectiveness of levosimendan in patients with exacerbation of chronic heart failure — a single-center perspective" @default.
- W3173728910 doi "https://doi.org/10.5603/mrj.2021.0027" @default.
- W3173728910 hasPublicationYear "2021" @default.
- W3173728910 type Work @default.
- W3173728910 sameAs 3173728910 @default.
- W3173728910 citedByCount "0" @default.
- W3173728910 crossrefType "journal-article" @default.
- W3173728910 hasAuthorship W3173728910A5005207274 @default.
- W3173728910 hasAuthorship W3173728910A5019858389 @default.
- W3173728910 hasAuthorship W3173728910A5029840046 @default.
- W3173728910 hasAuthorship W3173728910A5030036503 @default.
- W3173728910 hasAuthorship W3173728910A5050751424 @default.
- W3173728910 hasAuthorship W3173728910A5067935886 @default.
- W3173728910 hasAuthorship W3173728910A5090902698 @default.
- W3173728910 hasBestOaLocation W31737289101 @default.
- W3173728910 hasConcept C121955636 @default.
- W3173728910 hasConcept C126322002 @default.
- W3173728910 hasConcept C144133560 @default.
- W3173728910 hasConcept C164705383 @default.
- W3173728910 hasConcept C167135981 @default.
- W3173728910 hasConcept C177713679 @default.
- W3173728910 hasConcept C194828623 @default.
- W3173728910 hasConcept C23131810 @default.
- W3173728910 hasConcept C2777014857 @default.
- W3173728910 hasConcept C2777335384 @default.
- W3173728910 hasConcept C2778198053 @default.
- W3173728910 hasConcept C2780073493 @default.
- W3173728910 hasConcept C6964187 @default.
- W3173728910 hasConcept C71924100 @default.
- W3173728910 hasConceptScore W3173728910C121955636 @default.
- W3173728910 hasConceptScore W3173728910C126322002 @default.
- W3173728910 hasConceptScore W3173728910C144133560 @default.
- W3173728910 hasConceptScore W3173728910C164705383 @default.
- W3173728910 hasConceptScore W3173728910C167135981 @default.
- W3173728910 hasConceptScore W3173728910C177713679 @default.
- W3173728910 hasConceptScore W3173728910C194828623 @default.
- W3173728910 hasConceptScore W3173728910C23131810 @default.
- W3173728910 hasConceptScore W3173728910C2777014857 @default.
- W3173728910 hasConceptScore W3173728910C2777335384 @default.
- W3173728910 hasConceptScore W3173728910C2778198053 @default.
- W3173728910 hasConceptScore W3173728910C2780073493 @default.
- W3173728910 hasConceptScore W3173728910C6964187 @default.
- W3173728910 hasConceptScore W3173728910C71924100 @default.
- W3173728910 hasIssue "2" @default.
- W3173728910 hasLocation W31737289101 @default.
- W3173728910 hasOpenAccess W3173728910 @default.
- W3173728910 hasPrimaryLocation W31737289101 @default.
- W3173728910 hasRelatedWork W1941054595 @default.
- W3173728910 hasRelatedWork W2020088846 @default.
- W3173728910 hasRelatedWork W2125804349 @default.
- W3173728910 hasRelatedWork W2170995244 @default.
- W3173728910 hasRelatedWork W2276850597 @default.
- W3173728910 hasRelatedWork W2977769413 @default.
- W3173728910 hasRelatedWork W3173728910 @default.
- W3173728910 hasRelatedWork W4214517713 @default.
- W3173728910 hasRelatedWork W4319440053 @default.
- W3173728910 hasRelatedWork W4323807298 @default.
- W3173728910 hasVolume "6" @default.
- W3173728910 isParatext "false" @default.
- W3173728910 isRetracted "false" @default.
- W3173728910 magId "3173728910" @default.
- W3173728910 workType "article" @default.